New duvakitug data reinforce best-in-class potential

French drug major Sanofi (Euronext: SAN) and the US unit of Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).

These results were shared in two oral presentations at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO) in Berlin, Germany.

In the UC cohort of the RELIEVE UCCD study, 36% (450mg dose) and 48% (900mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo; placebo-adjusted rates were 16% (450 mg dose) and 27% (900 mg dose) (p=0.050 and 0.003, respectively.